Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) EBITDA (2023 - 2025)

Historic EBITDA for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to -$27.0 million.

  • Monte Rosa Therapeutics' EBITDA fell 1464.85% to -$27.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.0 million, marking a year-over-year increase of 11664.86%. This contributed to the annual value of -$73.3 million for FY2024, which is 4620.76% up from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported EBITDA of -$27.0 million as of Q3 2025, which was down 1464.85% from -$12.3 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' EBITDA's 5-year high stood at $46.9 million during Q1 2025, with a 5-year trough of -$35.4 million in Q2 2023.
  • Its 3-year average for EBITDA is -$18.4 million, with a median of -$30.3 million in 2024.
  • Over the last 5 years, Monte Rosa Therapeutics' EBITDA had its largest YoY gain of 24688.92% in 2025, and its largest YoY loss of 1464.85% in 2025.
  • Over the past 3 years, Monte Rosa Therapeutics' EBITDA (Quarter) stood at -$34.5 million in 2023, then soared by 135.93% to $12.4 million in 2024, then tumbled by 317.33% to -$27.0 million in 2025.
  • Its EBITDA was -$27.0 million in Q3 2025, compared to -$12.3 million in Q2 2025 and $46.9 million in Q1 2025.